Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Up 97.4% in April

Posted by George Bondi on May 17th, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 46,010 shares, a growth of 97.4% from the April 15th total of 23,312 shares. Based on an average trading volume of 31,445 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.9% of the shares of the stock are short sold.

Hedge Funds Weigh In On Neuphoria Therapeutics

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in shares of Neuphoria Therapeutics by 33.3% in the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after purchasing an additional 4,325 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of Neuphoria Therapeutics in the 3rd quarter valued at about $58,000. Commonwealth Equity Services LLC acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at about $43,000. XTX Topco Ltd acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at about $47,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at about $54,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, HC Wainwright lowered shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $21.00.

Read Our Latest Stock Analysis on Neuphoria Therapeutics

Neuphoria Therapeutics Trading Down 7.1%

NEUP stock traded down $0.36 during mid-day trading on Friday, reaching $4.73. 79,662 shares of the stock traded hands, compared to its average volume of 28,729. Neuphoria Therapeutics has a 52-week low of $3.64 and a 52-week high of $21.40. The company has a market cap of $25.49 million, a P/E ratio of -0.43 and a beta of 0.72. The stock’s fifty day moving average is $4.72 and its 200-day moving average is $4.38.

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) last issued its earnings results on Tuesday, May 19th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Equities research analysts expect that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Neuphoria Therapeutics Company Profile

(Get Free Report)

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.